A rare VIP-secreting tumor was found to cause the same type of heart valve damage usually seen only with classical carcinoid tumors.
0.05%–2%Incidence of VIPoma among neuroendocrine tumors — making this an exceptionally rare tumor type now linked to heart valve disease
What the researchers found
A patient with previously undiagnosed VIPoma was found to have tricuspid regurgitation and stenosis on echocardiography — cardiac valve changes typically associated with classical carcinoid syndrome but not historically seen with VIP-secreting tumors. The echocardiographic finding of carcinoid heart disease prompted the workup that ultimately led to the VIPoma diagnosis.
This is notable because VIPomas have an incidence of only 0.05%–2% of neuroendocrine tumors, and cardiac valve involvement has not been a recognized feature of these tumors. The case suggests that the spectrum of neuroendocrine tumors capable of causing carcinoid heart disease may be wider than previously understood.
Why it matters
This case challenges the assumption that only serotonin-secreting carcinoid tumors cause heart valve damage. If VIPomas can also produce carcinoid heart changes, clinicians may need to broaden their diagnostic thinking when they encounter unexplained tricuspid valve disease — potentially catching rare neuroendocrine tumors earlier.
The numbers in context
VIPoma incidence: 0.05%–2% of neuroendocrine tumors
How the study worked
Single patient case report published in BMJ Case Reports. The authors describe a patient whose echocardiogram revealed tricuspid regurgitation and stenosis, which prompted further investigation and ultimately led to the diagnosis of a VIP-secreting tumor.
Who was studied
Single patient with VIPoma presenting with carcinoid heart findings
What this study cannot tell us
As a single case report, this cannot establish a causal relationship between VIPoma and carcinoid heart disease. It is unclear whether the cardiac findings were directly caused by VIP secretion or by other co-secreted substances. No mechanism is proposed for how VIP might cause valvular changes.
How to read the evidence
This is a single case report, which provides the lowest level of clinical evidence. While it raises an interesting and potentially important observation, it cannot establish causation or generalizability.
When this study was published
Published in 2024, this is a recent case report documenting a novel clinical observation that has not yet been corroborated by larger studies.
The bigger picture
Neuroendocrine tumors release various peptide hormones into the bloodstream, and different tumor types are associated with different clinical syndromes. Heart valve damage has traditionally been linked only to serotonin-secreting tumors. This case expands the spectrum of neuroendocrine tumors that may affect the heart, which could influence screening protocols and diagnostic workups for patients with unexplained valvular disease.
Questions still open
- Could VIP itself directly damage heart valves, or is the damage mediated by other substances co-secreted by the tumor?
- Should patients diagnosed with VIPoma routinely undergo echocardiographic screening for cardiac involvement?
- How many VIPoma patients have undetected subclinical valve disease that has simply never been looked for?
Common questions
What is a VIPoma and how is it different from a typical carcinoid tumor?
What is carcinoid heart disease?
Read the original research
Carcinoid heart findings in vasoactive intestinal peptide-secreting tumour.
BMJ case reports, 17(11)
Citation
Joshi, Mugdha; Aldea, Daniel; Ngo, Peter; Shah, Sonia. (2024). Carcinoid heart findings in vasoactive intestinal peptide-secreting tumour.. BMJ case reports, 17(11). https://doi.org/10.1136/bcr-2024-262229